Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics Limited has announced the appointment of Hamish George as the new Chief Financial Officer, bringing his decade-long expertise in finance and commercial experience to the clinical-stage biotech company. George’s previous roles include Director at Bio101 Financial Advisory and CFO for multiple organizations, poised to aid the company’s development of novel psilocybin-based therapies. The company expressed gratitude to former CFO Jim O’Neill for his contributions and smooth transition of responsibilities to George.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.